MacroGenics Announces Date of Second Quarter 2022 Financial Results


ROCKVILLE, MD, July 25 10, 2022 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapies for the treatment of cancer, today announced that the company would release its second quarter 2022 financial results after market close on Monday, August 8, 2022. MacroGenics will host a conference call to discuss the company’s recent financial results and progress on Monday, August 8, 2022 at 4:30 p.m. AND.

Conference call information

To participate by telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number as well as a unique passcode and registration ID that can be used to access the call. The listen-only webcast of the conference call can be accessed under “Events and Presentations” in the Investor Relations section of the Company’s website at A recorded replay of the webcast will be available shortly after the call concludes and archived on the Company’s website for 30 days after the call.

About MacroGenics, Inc.

MacroGenics is a biopharmaceutical company specializing in the development and commercialization of innovative treatments based on monoclonal antibodies for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which apply to broad therapeutic areas. The combination of MacroGenics’ technology platforms and protein engineering expertise has enabled the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please visit the company’s website at MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.


Source link


Comments are closed.